Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript

Mark Frattini: Yes. So there’s some, , has will show on the poster. There’s a level of expansion that was seen with the cells by flow . At the time point of this event happen, we don’t believe there were any UCART22 cells record remaining. So we think that the likelihood it was less related to UCART22. This was a patient who was again, as outlined in the abstract, was super heavily pretreated, they failed alo transplant, they failed prior octalagus CAR-T. They failed multi-agent chemo in and they also failed blinatumomab or inotuzumab and venetoclax. So the cumulative dose in the prior chemo that they made and going into this study very high both cellular explained some of the issues that are developed.

Unidentified Analyst : That’s super helpful. Thank you so much.

Operator: Thank you. As there are no further questions, I would now hand the conference over to Andre Choulika, CEO for closing comments.

Andre Choulika: Well, first of all, I would like to thank the team for helping in doing the call here. It’s been a pleasure to prepare this together, and I would like very warmly thank all the analysts that have been following the covenants supporting in watching what we’re doing is very valuable. And I would like to make a special word of so to our long-term shareholders that has been continuously supporting the company over the past years. And I hope that to the company is going to have like a very strong end of ’23 and ’24 and ’25 and ’26. So we’ll come up very soon for an update on the progress. Thank you very much.

Operator: Thank you. The conference of Cellectis has now concluded. Thank you for your participation. You may now disconnect your lines.